Announcements Trials
Browse Landscape

Phase

Phase 2 204Phase 1 74Phase 1/2 32Phase 3 30Phase NA 7Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 1Leukemia 1Congenital Abnormalities 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × sargramostim × Clear all
NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

NCT00630565 2024-01-29

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2/3 Terminated
12 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡